12 mg subcutaneous daily , or 1 mg three times weekly , is the most commonly used GHK-Cu skin dose in published research and clinic practice
Response: Regarding commenters' requests for exclusion criteria, we note that the measure methodology, including consideration of potential exclusions, was informed by extensive literature review, empiric analyses, and feedback from the TEP, PFE Work Group, and the public comment period held during measure development
Dosing Phases & Cycling 5-Amino-1MQ is a metabolic-enzyme modulator, so the documented research pattern treats it as a run-in, steady-state, then off compound rather than something you pulse and stop
Discuss options with a clinician to match safety, evidence, and personal medical history